Market Cap
$7.9B
SYRE
Spyre Therapeutics, Inc.
$91.60 ▲ +1.86%
Prev close $89.93Market cap$7.9B
ConsensusStrong Buy
12-mo target$120.21 (+31.2%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)43 New Institutional Positions7 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SYRE right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$5.8B
Inst. Activity
43 buys / 7 sells
Insider Activity
$0.00 buy / $417.0M sell
Insider Net $
-$417.0M
SEC Reports
20
Press Releases
4
Price chart 30d +5.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Sep 4, 2026 SEC Short Volume: SYRE — 58.1% short (0.4M / 0.7M)
Short: 429,183 | Exempt: 4,000 | TRF Vol: 739,288 | Short Ratio: 58.1% | Off-exchange volume (dark p
CEO Cameron Turtle and CFO Scott Burrows sold a combined $810K in open-market sales on September 1, 2026. These sales fo
CLUSTER — Impact 5/10
Sep 2, 2026 Insider
King-Jones Heidy acquired via exercise 400 shares
See Remarks @ $14.50 ($5.8K)
Sep 2, 2026 Insider
King-Jones Heidy sold 400 shares
See Remarks @ $90.00 ($36.0K)
Sep 2, 2026 Insider
Aug 11, 2026 SEC Burrows Scott L sold 18,232 shares
Chief Financial Officer @ $89.35 ($1.6M)
Three insiders at Spyre Therapeutics, including the CEO and CFO, sold shares totaling $920K over a one-week window. Dire
CLUSTER — Impact 5/10
CEO Turtle Cameron and CFO Scott Burrows sold a combined $561K in open-market sales on August 3, 2026, with the CEO sell
CLUSTER — Impact 5/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
2,562,265 shares ($239.3M)
Analyst ratings buy % -4.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | JP Morgan | INITIATE | Overweight | 55% |
| Oct 1, 2026 | BTIG | REITERATE | Buy | 53% |
| Sep 9, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 8, 2026 | BTIG | REITERATE | Buy | 53% |
| Aug 26, 2026 | Deutsche Bank | MAINTAIN | Buy | 58% |
| Aug 26, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Aug 26, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Aug 11, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Aug 5, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 5, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 11 | 10 | 2 | 0 | 0 | 91% | |
| Aug 1, 2026 | 11 | 10 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 12 | 10 | 1 | 0 | 0 | 96% | |
| Jun 1, 2026 | 12 | 10 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 12 | 10 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 9 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 11 | 9 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 11 | 9 | 1 | 0 | 0 | 95% |
Price targets
Where 14 covering analysts think SYRE trades over the next 12 months.
$120.21 +31.2% upside Strong Buy
Current$91.60 Low$97.00 Median$122.00 High$130.00 14 analysts
$97.00$130.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 5 bullish, 5 bearish, 1 mixed, 9 neutral · avg impact 5.0/10.Plus 4 press releases.
BEARISHCLUSTER5/10
CEO Cameron Turtle and CFO Scott Burrows sold a combined $810K in open-market sales on September 1,
Sep 4, 2026
BEARISHCLUSTER5/10
Three insiders at Spyre Therapeutics, including the CEO and CFO, sold shares totaling $920K over a o
Aug 11, 2026
BEARISHCLUSTER5/10
CEO Turtle Cameron and CFO Scott Burrows sold a combined $561K in open-market sales on August 3, 202
Aug 6, 2026
NEUTRALS-3ASR5/10
{ "summary": "Spyre Therapeutics filed an automatic shelf registration statement (S-3ASR) on June
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: SYRE — 58.1% short (0.4M / 0.7M)
Short: 429,183 | Exempt: 4,000 | TRF Vol: 739,288 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: SYRE — 69.9% short (0.5M / 0.8M)
Short: 547,223 | Exempt: 20,762 | TRF Vol: 782,768 | Short Ratio: 69.9% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
ftd
FTD: SYRE — 24,790 shares ($2.2M) failed to deliver
Settlement: 20260910, Price: $86.93, FTD Value: $2,154,994.7, SPYRE THERAPEUTICS, INC. COMMO
Sep 8, 2026
short_volume
Short Volume: SYRE — 60.8% short (0.3M / 0.5M)
Short: 320,342 | Exempt: 1 | TRF Vol: 526,451 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Sep 4, 2026
other
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.83 | $-1.53–$-0.66 | -451.6% | -2.2% | 2↑ 8↓ | $0.0B | 13 |
| Next Q | $-0.87 | $-1.97–$-0.50 | -17.4% | -2.7% | 3↑ 9↓ | $0.0B | 13 |
| Current FY | $-2.87 | $-4.81–$-2.37 | -44.9% | -1.4% | 9↑ 3↓ | $0.0B | 13 |
| Next FY | $-3.52 | $-4.51–$-2.59 | -22.7% | -2.5% | 3↑ 8↓ | $0.0B | 13 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.827 | — |
| 7d ago | $-0.833 | +0.006 |
| 30d ago | $-0.810 | -0.017 |
| 60d ago | $-0.725 | -0.102 |
| 90d ago | $-0.725 | -0.102 |
Institutional ownership
Which big funds own SYRE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $5.8B total value (65,232,069 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 43 institutions added/increased vs 7 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 13,026,187 | $1.2B | 19.9% | — |
| BlackRock, Inc. | 6,506,605 | $577.7M | 10.0% | — |
| RTW INVESTMENTS, LP | 4,251,996 | $377.5M | 6.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,448,681 | $306.2M | 5.3% | — |
| STATE STREET CORP | 3,057,416 | $271.4M | 4.7% | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,799,166 | $248.5M | 4.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,562,265 | $239.3M | 4.1% | ADD +48.9% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,330,098 | $206.9M | 3.6% | DOUBLED +298.2% |
| Capital World Investors | 2,315,553 | $205.6M | 3.5% | DOUBLED +247.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 1,720,912 | 2,562,265 | +48.9% | $239.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 585,130 | 2,330,098 | +298.2% | $206.9M |
| Capital World Investors | DOUBLED | 666,564 | 2,315,553 | +247.4% | $205.6M |
| BANK OF AMERICA CORP /DE/ | ADD | 1,228,093 | 1,777,854 | +44.8% | $157.8M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 1,722,300 | — | $152.9M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 269,938 | 1,478,059 | +447.6% | $131.2M |
| Holocene Advisors, LP | NEW | — | 1,015,170 | — | $90.1M |
| MARSHALL WACE, LLP | DOUBLED | 139,259 | 991,693 | +612.1% | $88.0M |
| Capital International Investors | TRIM | 1,746,129 | 955,196 | -45.3% | $84.8M |
| UBS Group AG | ADD | 671,235 | 843,071 | +25.6% | $74.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$417.0M — $0.00 bought, $417.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | King-Jones Heidy | See Remarks | EXERCISE | 400 | $14.50 | $5.8K |
| Sep 2, 2026 | King-Jones Heidy | See Remarks | SELL | 400 | $90.00 | $36.0K |
| Sep 2, 2026 | Burrows Scott L | Chief Financial Officer | SELL | 18,232 | $89.35 | $1.6M |
| Sep 1, 2026 | King-Jones Heidy | See Remarks | SELL | 6,206 | $88.17 | $547.2K |
| Sep 1, 2026 | King-Jones Heidy | See Remarks | SELL | 4,845 | $86.40 | $418.6K |
| Sep 1, 2026 | King-Jones Heidy | See Remarks | EXERCISE | 27,999 | $14.50 | $406.0K |
| Sep 1, 2026 | King-Jones Heidy | See Remarks | SELL | 400 | $89.38 | $35.8K |
| Sep 1, 2026 | King-Jones Heidy | See Remarks | SELL | 16,548 | $87.20 | $1.4M |
| Sep 1, 2026 | Burrows Scott L | Chief Financial Officer | SELL | 200 | $89.04 | $17.8K |
| Sep 1, 2026 | Burrows Scott L | Chief Financial Officer | SELL | 2,016 | $88.03 | $177.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SYRE.
Shares short
12,129,443
Settlement Sep 15, 2026
Change vs prior
+2.3%
Semi-monthly cycle
Days to cover
11.6
At avg daily volume
Of shares outstanding
≈13.8%
Estimate — not % of float
All SYRE filing & press-release reports (26)
- CLUSTER reportSep 4, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 6, 2026
- S-3ASR reportJul 3, 2026
- CLUSTER reportJul 3, 2026
- CLUSTER reportJun 27, 2026
- CLUSTER reportJun 24, 2026
- 8-K reportJun 15, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 4, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 29, 2026
- CLUSTER reportMay 9, 2026
- 8-K reportMay 5, 2026
- CLUSTER reportMay 2, 2026
- PRESS-RELEASE reportApr 15, 2026
- 424B5 reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- 8-K reportApr 13, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- DEFA14A reportApr 10, 2026
- CLUSTER reportApr 4, 2026
- PRESS-RELEASE reportApr 3, 2026
- EFFECT reportMar 2, 2026